The estimated Net Worth of Lisa Delfini is at least $190 mil dollars as of 22 May 2024. Ms Delfini owns over 16,043 units of Trevi Therapeutics stock worth over $190,176 and over the last 3 years she sold TRVI stock worth over $0.
Ms has made over 10 trades of the Trevi Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 16,043 units of TRVI stock worth $8,182 on 22 May 2024.
The largest trade she's ever made was exercising 27,500 units of Trevi Therapeutics stock on 13 February 2023 worth over $14,025. On average, Ms trades about 4,420 units every 33 days since 2021. As of 22 May 2024 she still owns at least 57,629 units of Trevi Therapeutics stock.
You can see the complete history of Ms Delfini stock trades at the bottom of the page.
Lisa Delfini is the Chief Financial Officer at Trevi Therapeutics.
Ms Delfini is 51, she's been the Chief Financial Officer of Trevi Therapeutics since . There are 18 older and 1 younger executives at Trevi Therapeutics. The oldest executive at Trevi Therapeutics, Inc. is Anne VanLent, 72, who is the Independent Director.
Lisa's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.
Over the last 6 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett y Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics executives and other stock owners filed with the SEC include: